BDNF genotype and tDCS interaction in aphasia treatment

Julius Fridriksson a,*, Jordan Elm b, Brielle C. Stark a, Alexandra Basilakos a, Chris Rorden c, Souvik Sen d, Mark S. George e, f, g, Michelle Gottfried b, Leonardo Bonilha i

a Department of Communication Sciences & Disorders, University of South Carolina, USA
b Department of Public Health Sciences, Medical University of South Carolina, USA
c Department of Psychology, University of South Carolina, USA
d Department of Neurology, University of South Carolina, USA
e Department of Psychiatry, Medical University of South Carolina, USA
f Department of Neurology, Medical University of South Carolina, USA
g Ralph H. Johnson VA Medical Center, Charleston, USA

A R T I C L E   I N F O

Article history:
Received 23 May 2018
Received in revised form 13 August 2018
Accepted 14 August 2018
Available online 18 August 2018

Keywords:
Aphasia
Stroke
tDCS
Electrical brain stimulation
Rehabilitation
Aphasia treatment

A B S T R A C T

Background: Several studies, including a randomized controlled trial by our group, support applying anodal tDCS (A-tDCS) to the left hemisphere during behavioral aphasia treatment to improve outcomes. A clear mechanism explaining A-tDCS’s efficacy has not been established, but modulation of neuroplasticity may be involved.

Objective/hypothesis: The brain-derived neurotrophic factor (BDNF) gene influences neuroplasticity and may modulate the effects of tDCS. Utilizing data from our recently completed trial, we conducted a planned test of whether aphasia treatment outcome is influenced by interaction between A-tDCS and a single-nucleotide polymorphism of the BDNF gene, rs6265.

Methods: Seventy-four individuals with chronic stroke-induced aphasia completed 15 language therapy sessions and were randomized to receive 1 mA A-tDCS or sham tDCS (S-tDCS) to the intact left temporoparietal region for the first 20 min of each session. BDNF genotype was available for 67 participants: 37 participants had the typical val/val genotype. The remaining 30 participants had atypical BDNF genotype (Met allele carriers). The primary outcome factor was improvement in object naming at 1 week after treatment completion. Maintenance of treatment effects was evaluated at 4 and 24 weeks.

Results: An interaction was revealed between tDCS condition and genotype for treatment-related naming improvement (F = 4.97, p = 0.03). Participants with val/val genotype who received A-tDCS showed greater response to aphasia treatment than val/val participants who received S-tDCS, as well as the Met allele carriers, regardless of tDCS condition.

Conclusion: Individuals with the val/val BDNF genotype are more likely to benefit from A-tDCS during aphasia treatment.

© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Aphasia is a language problem typically caused by damage to the cortical language network. Even for individuals with relatively mild aphasia, the effects on communication abilities are often profound, and, by extension, affect employment opportunities and overall quality of life. Aphasia is present in approximately 30% of all cases of acute stroke [1], and it is estimated that over two million long-term stroke survivors are living with chronic aphasia in the United States [2]. Most people who persist with chronic aphasia never fully recover, especially those with moderate or severe impairment. Although the incidence of stroke is declining among older adults, the overall prevalence of stroke is not decreasing, as stroke incidence is increasing among younger adults, and life expectancy is increasing [3]. Consequently, the societal effects of aphasia are increasing as younger individuals are likely to live longer with aphasia compared to those who acquire aphasia at a later age.

The standard of care for aphasia is behavioral speech-language treatment (aphasia treatment), which is usually administered by a speech-language pathologist in a one-on-one setting. The effectiveness of aphasia treatment is supported by randomized
controlled trials (RCT) and meta-analyses of treatment studies [1]. A recent RCT showed that three weeks of speech-language treatment compared to deferred treatment improves verbal communication (Cohen’s $d = 0.58$) and communication quality of life (Cohen’s $d = 0.21$) in chronic aphasia [4]. Although these data are encouraging, the effect sizes are somewhat small, which may result in only modest improvements in many cases. Therefore, it is crucial to find ways to improve the effectiveness of aphasia treatment.

One method that has shown promising results in enhancing the effects of aphasia treatment is transcranial direct current stimulation (tDCS). The first study to combine aphasia treatment and A-tDCS found that 1 mA stimulation targeting the left frontal lobe improved the effect of naming treatment over sham tDCS (S-tDCS) immediately at the conclusion of treatment and at one week post-treatment [5]. A follow-up study using A-tDCS applied to posterior regions of the left hemisphere during aphasia treatment resulted in improved naming reaction times compared to S-tDCS [6]. A-tDCS applied to the left motor cortex during aphasia treatment was also shown to result in greater improvement in naming of trained and untrained items at 6 months after treatment completion [7]. Notably, the treatment effect generalized to improvements in functional communication.

Most of the early studies on A-tDCS and aphasia included only a small number of participants [5,8–12]. This was the motivation for the much larger and more definitive double-blinded RCT comparing the outcome of three weeks of aphasia treatment (5 days/week) in a group of chronic post-stroke participants with aphasia who were randomized to receive A-tDCS ($N = 34$) or S-tDCS ($N = 40$) [13]. This study utilized a futility design: the null hypothesis stated that A-tDCS results in better aphasia treatment outcome than S-tDCS, whereas the alternative hypothesis stated that there is no evidence that A-tDCS is superior to S-tDCS. The primary analysis was adjusted for aphasia severity using the Aphasia Quotient (AQ) from the Western Aphasia Battery, Revised (WAB-R [14]). The results of this RCT were: participants who received A-tDCS, compared to those who received S-tDCS, had large improvements in naming of trained and untrained items at one-week (70% higher), 4 weeks- (79% higher), and 24 weeks- (110% higher) post treatment. Crucially, the futility hypothesis was not supported by the data, suggesting that further study of A-tDCS to enhance aphasia treatment is warranted.

Along with previous studies of this kind, our RCT suggests A-tDCS may enhance the effects of aphasia treatment. Although we believe these findings are promising, very little is known about why adjunctive A-tDCS boosts the effect of the behavioral treatment. A considerable body of evidence suggests aphasia treatment leads to both functional and structural changes in the cortex [15–20]. One mechanism by which A-tDCS may work is by modulating brain plasticity; for example, at the level of synaptic activity [21,22]. Relying on a mouse model, a study by Fritsch et al. [21] showed that anodal direct current stimulation (DCS) administered for 15 min paired with simultaneous synaptic activation lead to an increase in postsynaptic potentials in M1 slices. This increase lasted at least 2 h beyond the termination of the DCS. Crucially, Fritsch et al.’s study showed that activity-dependent secretion of brain derived neurotrophic factor (BDNF) is necessary for long-term synaptic plasticity induced by DCS.

BDNF is encoded by the BDNF gene, and a common single-nucleotide polymorphism (SNP), rs6265 (also called val66met or val/met), is associated with an 18–30% reduction in secretion of BDNF in humans [23]. Among Caucasians, the ratio of typical BDNF genotype (val/val) to atypical BDNF genotype (val/met or met/met; i.e., “Met allele carriers”) is approximately 65/35 (see Petryshen et al. [24] of proportion of rs6265 in different ethnic and racial groups). The presence of the Met allele is associated with poorer memory performance [25,26] and decreased plasticity of the motor cortex [27,28]. In stroke patients, the Met allele has been associated with poorer motor rehabilitation outcome in patients with moderate-mild impairment [29], poorer learning of a novel motor task [30], as well as lower ipsilateral cortical brain activation [31]. If A-tDCS enhances synaptic plasticity during aphasia treatment, it is straightforward to suggest that individuals with typical BDNF genotype on SNP rs6265 (val/met or met/met) would benefit more from adjunct A-tDCS during aphasia treatment compared to those with atypical BDNF genotype.

The purpose of the current study was to test whether response to A-tDCS to preserved left hemisphere tempo-parietal regions during aphasia treatment is BDNF genotype specific. The data presented here were collected as part of the aforementioned RCT trial on A-tDCS and aphasia treatment [13]. We hypothesized that an interaction would exist between tDCS condition (A-tDCS vs. S-tDCS) and BDNF genotype (typical BDNF genotype [val/val] vs. atypical BDNF genotype [val/met or met/met]). Specifically, we expected that participants with typical BDNF genotype receiving A-tDCS would respond better to aphasia treatment (demonstrate greater improvements in object naming post-therapy) compared to those with i) typical BDNF genotype who received S-tDCS, and ii) participants with atypical genotype (Met allele carriers), regardless of tDCS condition. In addition, based on studies that suggest BDNF genotype influences overall learning [25,28,29,32], we expected a main effect of BDNF genotype on aphasia treatment outcome.

1. Methods

Participants: Seventy-four participants were included in the RCT, which was performed at the University of South Carolina (USC) and at the Medical University of South Carolina (MUSC). BDNF genotype was available for 67 participants due to lost or contaminated sample (6 participants) or decline in blood draw (1 participant). One participant with typical BDNF genotype (val/val) discontinued the study before completing the treatment phase. Therefore, BDNF genotype and post-treatment assessment data were available for 66 participants. For greater detail on the background, methods, and results of the primary outcome of the RCT, readers are referred to Fridriksson et al. [13].

BDNF genotyping: During each participant’s first session for neuroimaging and behavioral testing, 2 mL of whole blood were collected. The blood sample was labeled with each participant’s de-identified study number and frozen. All samples were sent in one batch to DNA Genotek (https://www.dnagenotek.com/), where DNA extraction and SNP genotyping was completed on rs6265. Blood samples were extracted using Qiagen PureGene reagents and a validated extraction protocol. Genotyping for the SNP was accomplished using a TaqMan® single tube genotyping assay. The TaqMan assay is an allele discrimination assay using PCR amplification and a pair of fluorescent dye detectors that target the SNP. One fluorescent dye is attached to the detector that is a perfect match to the first allele (e.g. an “A” nucleotide) and a different fluorescent dye is attached to the detector that is a perfect match to the second allele (e.g. a “C” nucleotide). During PCr, the polymerase releases the fluorescent probe into solution where it is detected using endpoint analysis in a Life Technologies, Inc. (Foster City, CA) 7900HT Real-Time instrument. Primers and probes were obtained through Life Technologies design and manufacturing. Genotypes were determined using Life Technologies’ Taqman Genotyper v1.0.1

1 Consistent with Fritsch et al. [21], participants were divided into groups based on whether they were carriers of the Met Allele: typical BDNF gene (val/val) vs. atypical BDNF gene (val/met or met/met).
software. Participants with a val/val (e.g. “C/C”) expression were considered typical BDNF genotype and those with val/met (e.g. “C/A”) or met/met (e.g. “A/A”) were considered to have atypical BDNF genotype. Samples were then destroyed as per protocol.

**Aphasia treatment and tDCS:** The aphasia treatment consisted of a computerized picture-word matching task, administered 5 times/week for three weeks [33]. For each trial, participants viewed a picture of an everyday object, followed by an audiovisual model of a speaker saying a word (only the mouth of the speaker was displayed [33]). The participant then indicated, via button press, whether the audiovisual input matched the picture displayed (i.e., pressing a green button for correct matches and a red button for incorrect matches). The treatment paradigm included 160 trials, composed of low-, medium-, and high-frequency words. Immediate feedback was provided following each trial so participants could self-monitor their performance. Treatment session duration was approximately 45 min. Two tests of naming were selected as the primary outcome measure: 1. A picture naming test consisting of 80 items selected from the aphasia treatment paradigm; for the sake of brevity, we refer to this test as ‘ Naming 80,’ and 2. The Philadelphia Naming Test (PNT), which is also a picture naming test and is widely used in the literature [34]. The PNT includes 175 ‘untreated’ items and potential participants were excluded from study enrollment if the correctly named more than 140 pictures at baseline (to allow room for treatment-related improvement). Both the Naming 80 and PNT were administered twice at baseline, on two separate days, and then twice at each of the following post-treatment time points: 1 week, 4 weeks, and 24 weeks (also on two separate days). Here, we report results combined for trained items (Naming 80) and untrained items (PNT) for a total of 255 items. The proportional improvement in naming was calculated as pre-to-post treatment changes in naming divided by the potential improvement at baseline. Specifically, the number of correctly named items at baseline was subtracted from the number of correctly named items after treatment. Then, this difference was divided by the difference between the number of items named correctly at baseline and possible maximum score on the tests, 255 For example, if a participant named, on average, 55 items at baseline and then named 105 items at 1 week post-treatment, her proportional improvement was calculated as: 

\[
\frac{(105-55)}{(255-55)} = 0.25.
\]

At the beginning of the behavioral task, participants received 20 min of A-tDCS or S-tDCS, depending on their group assignment. Randomizations were performed with the randomization algorithm that utilized minimal sufficient balancing to ensure that participants at both testing sites (USC and MUSC) were balanced by baseline age, as well as aphasia type and severity. Among the 66 participants whose genotype was analyzed, 29 were randomized to receive A-tDCS and 37 were randomized to receive S-tDCS (Fig. 1). A relationship was not revealed between the distributions of genotype and race, \(X^2 = 3.2, p = 0.20\). This was a double-blind study - all investigators, clinicians (including those who scored the outcome measures), study coordinators, and participants were blind to tDCS condition assignment.

A constant current stimulator (Phoresor® II PM850; Iomed® Inc., Salt Lake City, Utah) was used for A-tDCS application. In-house hardware was used to mask treatment type so A-tDCS and S-tDCS setups did not differ in appearance. All participants were fitted with 5 × 5 cm saline soaked sponges (electrodes) at two sites: i) the anode site was the location of the left scalp that was coregistered to the brain region with the highest naming-related activation from a baseline fMRI (for more details on the MRI setup see Ref. [35]), and ii) the cathode was always placed on the right supraorbital forehead region. The mean location of stimulation was in the temporo-parietal junction. Mean coordinate locations (MNI coordinates, XYZ in mm) for each stimulation group were as follows: A-tDCS: 

-49, -50, 15; SD = 10, 19, 19; S-tDCS: -50, -50, 11; SD = 10, 19, 19; and mean coordinate location across all participants was -40, -50, 12; SD = 9, 18, 18. Participants in the active condition received A-tDCS for the first 20 min of the 45-min language treatment session. To blind participants who received S-tDCS to condition, a brief scalp sensation (30 s, with a gradual decrease over 15 s) was induced for all participants at the beginning of the language treatment session. TDCS setup and treatment procedures were identical for all participants, regardless of A-tDCS or S-tDCS. Complete details are provided in Fridriksson et al. [13].

**Statistical analyses:** Descriptive statistics and two-sample t-tests were used to compare BDNF genotype status for participant characteristics at baseline. A mixed effects linear model of the repeated measures of proportional change in correct naming (calculated as described above) was fit with the following independent variables: tDCS condition (A-tDCS or S-tDCS), BDNF genotype status (typical or atypical), tDCS x BDNF, time of testing (1 week post-, 4 weeks post-, 24 weeks post-treatment), tDCS x time, BDNF Genotype x tDCS x time, baseline WAB-AQ, and lesion size (time was considered a classification variable using SAS v 9.4 PROC MIXED repeated time/AR(1)). As revealed in Fridriksson et al. [13], WAB-AQ was associated with treatment outcome, in that participants with milder aphasia tended to improve more on the naming outcome tests (\(p = 0.01\)). Therefore, we included WAB-AQ as a cofactor in the mixed models.

**2. Results**

Among the 66 participants included in this analysis, 36 (55%) had typical BDNF genotype and 30 (45%) had atypical BDNF genotype, carrying the met allele. Racial distribution was as follows: 57 Caucasian, 7 African-American, and 2 Asian. Twenty participants were women and the mean age was 59.8 (SD: 10.2; range: 30–77).
The mean education level was 14.8 years (SD: 2.46; range: 10–20) and the mean time post-stroke was 43.3 months (SD: 41.1; range: 6.1–204.9). Baseline neuropsychological testing included the following: WAB-R [14] to determine aphasia type and severity (AQ mean: 58.9; SD: 19.9; range: 20.1–93.7); National Institutes of Health Stroke Scale to assess overall stroke severity (NIHSS; mean: 5; SD: 3; range: 1–14); Pyramids and Palm Trees Test [36] to assess semantic processing (PPTT; mean: 46.3/52; SD: 3.94; range: 34–52); and matrix sub-test on the Wechsler Adult Intelligence Scale-3rd Edition to test executive functioning [37] (WAIS-III; mean: 11.9; SD: 5.4; range: 3–23).

Atypical BDNF genotype was associated with more severe language impairment at baseline (Table 1). Aphasia severity was considerably milder in the participants with typical BDNF as demonstrated by a mean WAB-AQ that was more than 12 points higher than their counterparts who had atypical BDNF. The atypical BDNF participants also scored significantly lower on the Naming 80 and PNT, indicating that they had more severe anoma than typical BDNF participants. In contrast, no performance differences were found between the groups on the PPTT, the matrix subtest of the WAIS-III, or in stroke severity as indexed by NIHSS score. Similarly, no group differences were found for other factors such as age, lesion size, education, or time post stroke.

Based on the repeated measures mixed model, an interaction between BDNF genotype and tDCS condition was revealed for naming improvement (Table 2). Participants with typical BDNF genotype who received A-tDCS during the aphasia treatment improved more than those with typical BDNF genotype but received S-tDCS (Fig. 2). The participants with typical BDNF genotype who received A-tDCS also improved more than participants with atypical genotype, regardless of tDCS condition.

Moreover, a main effect was not found for BDNF genotype or tDCS condition (Table 2). In contrast, a main effect of time of follow-up testing was observed. The proportional improvement was fairly stable over time. Interaction effects were not revealed for tDCS condition vs. time of testing or a three-way interaction between BDNF genotype, tDCS condition, and time of testing.

3. Discussion

The analyses revealed two significant effects. First, there was an unexpected baseline difference, such that individuals with typical BDNF tended to have milder symptoms. Second, we found the predicted interaction, where individuals who had both typical BDNF as well as A-tDCS demonstrated better improvement.

A baseline difference in language performance between carriers of typical or atypical BDNF gene was an unexpected finding as others have not revealed similar results. A study by de Boer et al. [38] found neither baseline nor overall recovery differences in a group of 53 patients with stroke induced aphasia. However, there was one crucial difference between their research and the current study: Baseline examination of the patients in the de Boers et al. study occurred within one-month post-stroke and aphasia treatment commenced immediately thereafter. If BDNF genotype influences recovery in aphasia, it is possible that its effects are too subtle to be detected so soon after stroke. Specifically, had de Boers et al. [38] followed their patients several years post stroke, it is possible that the effects of BDNF genotype may have been detected. In the current study, the average time post-stroke at enrollment was greater than 3.5 years. The difference in activity dependent BDNF secretion by BDNF genotype may be too subtle (18–30%) to be detected except on a relatively long timescale. This point is supported by the current data where a main effect was not detected for BDNF genotype on the outcome of aphasia treatment dispensed over three weeks.

Although baseline differences in aphasia severity were revealed between the two BDNF genotype groups, no differences were noted on the NIHSS, a measure of overall stroke severity. In this context, it is important to note that among the participants included here, aphasia was the most pronounced stroke impairment measured on the NIHSS, in most cases. In fact, the primary inclusion criterion was presence of aphasia and potential participants were excluded if their naming abilities were too mild in order to avoid ceiling effects on the dependent measures. Language impairment is only assessed on one of the 11 items that comprise the NIHSS. Therefore, the NIHSS may not have been sensitive enough to detect group differences among participants whose most common behavioral impairment was aphasia. If we assume the two genotype groups were similar with regard to aphasia severity at the time of stroke, a difference in recovery of more than 12 AQ points constitutes a fairly pronounced effect of BDNF genotype. In most cases, experienced clinicians would probably notice an AQ difference of 12 points between patients and, we speculate, that its impact would probably surpass a ’minimum clinically significant difference.’ However, because the participants included here were not followed since the time of their stroke, we cannot definitively state that those aphasia severity differences reflect genotype differences. Although not statistically significant, the group with atypical BDNF genotype had numerically larger cortical damage and was not as far post-stroke, which are factors that may relate to long-term outcome [39]. However, those same participants also tended to be younger than those with typical BDNF genotype, which indicates a more favorable recovery from stroke and aphasia [40–42]. It should be noted that the baseline difference on language measures was not

### Table 1

Baseline data for participants with typical or atypical BDNF genotype. A two-sided t-test was used to compare the two groups on each baseline behavioral test, age, years of education, and lesion size. Significant group differences are highlighted by bolded text for the p-values in the last column.

| Baseline Characteristic | Typical BDNF genotype (val/val) N = 36 | Atypical BDNF genotype (val/met, met/met) N = 30 | Two sided p-value |
|-------------------------|----------------------------------------|-----------------------------------------------|------------------|
| WAB-R AQ                | Mean 63.5 SD 18.6 Lower 57.2 CI 69.8   | Mean 52.2 SD 19.3 Lower 45.0 CI 59.4          | 0.01             |
| Naming 80 (treated items) | Mean 23.0 SD 18.0 Lower 16.9 CI 29.1 | Mean 14.4 SD 15 Lower 8.8 CI 20               | 0.03             |
| Philadelphia Naming Test | Mean 69.3 SD 45.0 Lower 54.1 CI 84.5 | Mean 48.6 SD 38 Lower 34.4 CI 62.8            | 0.04             |
| PNT + Naming 80 | Mean 92.3 SD 62.4 Lower 71.2 CI 113.4 | Mean 63.0 SD 52.4 Lower 43.4 CI 82.5          | 0.04             |
| PPTT Total Score        | Mean 46.6 SD 3.4 Lower 45.4 CI 47.7   | Mean 46.1 SD 4.6 Lower 44.4 CI 47.8           | 0.65             |
| WAIS III Matrix Score   | Mean 12.4 SD 5.8 Lower 10.5 CI 14.4   | Mean 11.6 SD 4.5 Lower 9.7 CI 13.4            | 0.63             |
| NIH Stroke Scale        | Mean 4.8 SD 2.9 Lower 3.8 CI 5.8      | Mean 5.2 SD 3.4 Lower 4 CI 6.5                | 0.55             |
| Age                     | Mean 61.9 SD 9.2 Lower 58.8 CI 65.0   | Mean 57.3 SD 11.1 Lower 53.2 CI 61.5          | 0.07             |
| Years of Education      | Mean 14.8 SD 2.1 Lower 14.1 CI 15.5   | Mean 14.9 SD 2.8 Lower 13.9 CI 16             | 0.74             |
| Time post stroke (months) | Mean 50.3 SD 3.5 Lower 35.9 CI 64.8 | Mean 35.5 SD 38.9 Lower 21.0 CI 50.0          | 0.16             |
| Lesion Size             | Mean 118.5 SD 62.8 Lower 87.3 CI 139.8 | Mean 141.6 SD 84 Lower 119 CI 172             | 0.17             |

When adjusting for time post stroke and lesion size the main effect of BDNF genotype on WAB-R AQ and PNT + Naming 80 is no longer statistically significant (p = 0.11, p = 0.17, respectively).
Among participants who were randomized to receive A-tDCS during the aphasia treatment, those with typical BDNF genotype benefitted more from the language treatment than those with atypical BDNF genotype. As was stated earlier, atypical BDNF genotype is associated with lower levels of activity dependent BDNF secretion. Therefore, it is possible that A-tDCS boosts the effect of aphasia treatment by modulating long-term synaptic plasticity, a process that relies on BDNF secretion. Accordingly, participants who received A-tDCS but had atypical BDNF genotype did not respond as well to aphasia treatment because of lower production of BDNF. A comparison between the two genotypes among participants who received S-tDCS did not reveal a difference in treatment outcome. In fact, among the participants who received S-tDCS, those with typical BDNF genotype actually improved less than participants with atypical BDNF genotype, although this difference was not statistically significant. These findings are in agreement with what Fritsch et al. [21] found in a mouse model: A-tDCS has a neuroplastic effect that is BDNF dependent.

So far, one other study has examined BDNF and tDCS in aphasia treatment outcome [44]. Marangolo and colleagues [44] tested whether tDCS, both anodal and cathodal, administered during language treatment, modulated serum BDNF levels in seven participants with chronic aphasia. Although a positive effect of tDCS was found for aphasia treatment outcome, no changes in serum levels of BDNF were detected. If these findings are confirmed in larger studies, it could mean that A-tDCS does not actually alter the secretion of BDNF. Rather, it could be the case that the neuroplastic effect of A-tDCS is dependent on baseline levels of BDNF secretion; accordingly, participants in the A-tDCS group who have typical BDNF genotype and higher levels of BDNF secretion benefit more from the aphasia treatment than their counterparts who have atypical BDNF genotype and lower levels of BDNF secretion. This would also explain why participants in the S-tDCS group benefitted less from the aphasia treatment. However, Marongolo et al. tested serum levels of BDNF but did not verify BDNF genotype in their participants. Given that this study only included seven participants, it is possible that their null result was driven by including a significant proportion of participants with atypical BDNF genotype. Therefore, we cannot adjudicate whether the beneficial effect of A-tDCS seen in the current study is driven by baseline levels of BDNF or whether A-tDCS actually modulates the levels of BDNF. At the very least, our study provides motivation to examine this issue in greater detail in a targeted experiment.

Studies that have applied A-tDCS during aphasia treatment have targeted several different cortical regions, including the left inferior frontal gyrus [10,45], motor cortex [7], and posterior language cortex [6,11,46]. If, as our data may suggest, A-tDCS promotes BDNF driven neuroplasticity, our study provides strong evidence that modulation of residual language cortex promotes aphasia recovery. Compared to the right hemisphere or left hemisphere regions outside of the language network, we believe that plastic changes in residual language cortex promote the best aphasia treatment outcome. A relatively large body of research has focused on changes in cortical activity and structure associated with aphasia treatment outcome [15–20]. Most of these studies have focused on single cases or relatively small group of participants. However, the largest
studies in this area [16,47] suggest that preservation and modulation of residual language cortex is crucial for better aphasia treatment outcome. Along with the current study, these findings represent emerging evidence that improved lexical-semantic processing associated with aphasia treatment is driven by changes in residual language cortex in the left hemisphere. Moreover, the current results provide a clear cortical candidate to target in future studies and, if supported by further data, in clinical practice.

Conflicts of interest

The authors report no conflicts of interest with this work.

Acknowledgements

This work was supported by: National Institute on Deafness and Other Communication Disorders (PI Fridriksson: U01 DC011739), Co-author AB supported by NIH T32 DC014435 (trainee).

References

[1] Brady MC, Kelly H, Godwin J, Enderby P, Campbell P. Speech and language therapy for aphasia following stroke. Cochrane Libr 2016;6: https://doi.org/10.1002/14651858.CD004254.pub4.
[2] Transcranial-Mackie NA. Aphasia in North America. Moorstown NJ: Aphasia Access; 2018.
[3] Ramirez I, Kim-Tenser MA, Sanossian N, Sen S, Wen G, He S, et al. Trends in acute ischemic stroke hospitalizations in the United States. J Am Heart Assoc 2016;5(5), e003233.
[4] Breitenstein C, Grewe T, Floel A, Ziegler W, Springer L, Martus P, et al. Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting. Lancet 2017;389(10078):1526–38.
[5] Baker JM, Rorden C, Fredriksson J. Using transcranial direct-current stimulation to treat stroke patients with aphasia. Stroke 2010;41(6):1229–36.
[6] Fredriksson J, Richardson JD, Baker JM, Rorden C. Transcranial direct current stimulation improves naming reaction time in fluent aphasia: a double-blind, sham-controlled study. Stroke 2011;42(3):819–21.
[7] Meinen M, Darkow R, Lindenberg R, Floel A. Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia. Brain 2016;139(4):1152–63.
[8] Holland R, Leff AP, Josephs O, Galea JM, Desikan M, Price CJ, et al. Speech facilitation by left inferior frontal cortical stimulation. Curr Biol 2011;21(16):1403–7.
[9] Floel A, Meinen M, Kirstein R, Nijhof S, Deppe M, Knecht S, et al. Short-term anoma training and electrical brain stimulation. Stroke 2011;42(7):2065–7.
[10] Marangolo P, Marinelli C, Bonilha L, Baker JM, Moser D, Rorden C. Activity in preserved left hemisphere regions in chronic aphasia and the BDNF Val66Met polymorphism. Cereb Cortex 2012;25(10):2591–604.
[11] Fritsch B, Reis J, Martinowich K, Schambra HM, Yi J, Cohen LG, et al. Direct current stimulation promotes BDNF-dependent synaptic plasticity: potential implications for motor learning. Neuro 2010;66(2):198–204.
[12] Fillmer HL, Dux PE, Mattingley JB. Applications of transcranial direct current stimulation for understanding brain function. Trends Neurosci 2014;37(12):742–53.
[13] Chen Z-Y, Jing D, Bath KG, Ismail A, Khan T, Siao C-J, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2017;354(6314):140–3.
[14] Petryshyn TL, Saberi PC, Aldinger K, Fry B, Fan JB, Schaffner SF, et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry 2015;19(8):810.
[15] Marangolo P, Goldberg TE, Mattay VS, Kolacahna BS, Callicott JH, Egan MF, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. Neurosci 2003;25(17):2304–9.
[16] Ho R-C, Miley P, O’Leary DS, Librant A, Andreasen NC, Wassink TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatr 2006;63(7):731–40.
[17] Klein JA, Chan S, Pringle E, Schlatter K, Procaccio V, Jimenez R, et al. BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex. Nat Neurosci 2006;9(5):735.
[18] McHughen SA, Rodriguez PF, Klein JA, Klein ED, Crespo LM, Procaccio V, et al. BDNF val66met polymorphism influences motor system function in the human brain. Cereb Cortex 2009;20(5):1254–62.
[19] Lam AY, Foy C, Koles KE, Bujiacs AC, Tulsky JS, Schofield PR, McNulty PA. BDNF genotype interacts with motor function to influence rehabilitation responsiveness poststroke. Front Neurol 2016;7:69.
[20] Helm EE, Tyrell CM, Pohlig RT, Brady LD, Reisman DS. The presence of a single-nucleotide polymorphism in the BDNF gene affects the rate of locomotor adaptation after stroke. Exp Brain Res 2016;234(2):341–51.
[21] Kim DY, Quinlan EB, Gramer R, Cramer SC. BDNF Val66Met polymorphism is related to motor system function after stroke. Phys Ther 2016;96(4):533–9.
[22] Lam AY, McKay NS, Thompson CS, Hamm JP, Walde KE, Kirk JJ. Brain-derived neurotrophic factor Val66Met polymorphism, human memory, and synaptic neuroplasticity. Wiley Interdiscip Rev: Cogn Sci 2015;6(2):97–108.
[23] Fredriksson J, Baker JM, Whiteside J, Eoute Jr D, Moser D, Vesselinov R, et al. Treating visual speech perception to improve speech production in nonfluent aphasia. Stroke 2009;40(3):853–8.
[24] Roach A, Schwartz MF, Martin N, Grewal RS, Brecher A. The Philadelphia naming test: scoring and reliability. Clin Aphasiology 1996;24:121–34.
[25] Fredriksson J, Bonilha L, Baker JM, Moser D, Rorden C. Activity in preserved left hemisphere regions predicts anoma severity in aphasia. Cereb Cortex 2010;20(5):1013–9.
[26] Howard D, Patterson K. The Pyramids and Palm Trees Test: a test of semantic access from words and pictures. Cambridge: Thames Valley Test Company; 1992.
[27] Wechsler D. Wechsler adult intelligence scale–Third Edition (WAS–III). San Antonio, TX: NCS Pearson; 1997.
[28] de Boer RC, Speelman K, Heijemrink-Kal MH, van der Vliet R, Ribbers GM, van den Sandt-Koenderman WME. The role of the BDNF Val66Met polymorphism in recovery of aphasia after stroke. Neurorehabilitation Neural Repair 2011;25(3):319–25.
[29] Ellis C, Dismuke D, Edwards KK. Longitudinal trends in aphasia in the United States. J Am Heart Assoc 2017;6(1):e003615.
[30] Fridriksson J, assistant AB supported by NIH T32 DC014435 (trainee).